LGVN

• Clinical Development Milestones

  • The company's top near-term priority is the top-line data readout from the Phase IIb ELPAS-2 trial of laramester cell for hypoplastic left heart syndrome (HLHS), expected in mid-September 2026. The trial includes all objective clinical endpoints requested by the FDA: all-cause mortality, cardiac transplant-free survival, and major adverse cardiac events.
  • The investigational new drug (IND) application for laramester cell in pediatric dilated cardiomyopathy (PDCM) became effective in July 2025. The company is planning for a potential Phase 2 trial initiation in 2027, with the FDA allowing direct advancement to a single Phase 2 registration trial due to the severe unmet need of this rare disease.
  • Positive published clinical data showing laramester cell improves six-minute walk distance in age-related frailty led to Longeveron's selection as a finalist for the $101 million XPRIZE HealthSpan competition, selected from over 600 applicants across 58 countries. The company will receive $1 million to advance the program into the competition's final phase, with a potential $81 million grand prize for the winner.

• Scientific and Intellectual Property Updates

  • Laramester cell is backed by 52 issued patents and over 60 pending patents globally, with five FDA expedited designations: Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease.
  • Positive preliminary data from completed trials has been published in leading peer-reviewed journals including Nature Medicine and Cell Stem Cell.

• Corporate Strategy

  • Management is actively exploring potential development and commercialization partnerships to unlock full asset value, leveraging the infrastructure, capital, and global reach of established pharmaceutical partners. Partner discussions are already underway ahead of the ELPAS-2 readout.

• Cash runway: Existing cash and cash equivalents as of June 30, 2026 are expected to fund operating expenses and capital expenditures into the fourth quarter of 2026, based on the current operating budget.
• Clinical timeline: Top-line data from the ELPAS-2 Phase IIb trial for HLHS is confirmed to be released in mid-September 2026, delayed slightly from an original August target due to delays in 12-month MRI data collection for the last patient visit. A long-term extension trial for ELPAS-2 patients (following patients up to age 10) is in planning, with feasibility work ongoing after feedback from the FDA.
• Strategic path: If ELPAS-2 yields positive data, management plans to pursue partnering discussions immediately, with a goal of advancing to a BLA submission for HLHS, with an available priority review voucher from the rare pediatric disease designation.

Longeveron is a clinical-stage biotech developing stem cell therapies across four programs and does not generate meaningful product revenue. Total total revenue for Q2 2026 was $0.3 million, a 10% decrease from $0.329 million in Q2 2025. The decline was driven by the absence of contract manufacturing revenue in the 2026 period. Operating expenses are grouped into general & administrative (G&A) and research & development (R&D): G&A expenses were $3.2 million in Q2 2026, a 23% increase from $2.6 million in Q2 2025, driven by a $0.4 million rise in legal spending and a $0.2 million increase in personnel costs. R&D expenses were $3.2 million in Q2 2026, a 7% increase from $3 million in Q2 2025, attributed to higher clinical trial costs for the ELPAS-2 trial. Net loss for Q2 2026 was $6.1 million, a 22% increase from $5.0 million in Q2 2025. As of June 30, 2026, cash and cash equivalents totaled $10.1 million.

• The company is currently operating with limited cash, with runway only extending to Q4 2026, creating near-term financing risk without successful partnership or additional capital raising.
• Clinical and regulatory risk remains for the ELPAS-2 trial: the primary endpoint (right ventricular ejection fraction, RVEF) may not meet statistical significance, and while the FDA has indicated regulatory flexibility for clinically meaningful secondary endpoints, there is no guarantee of approval even if secondary endpoints are positive.
• Final alignment of the statistical analysis plan (SAP) with the FDA is still pending ahead of database unblinding, though management notes all prior feedback has been incorporated and no unresolved issues remain as of the call.

Q: For HLHS, what is the timeline for regulatory submission with positive ELPAS-2 data, what is the status of commercial manufacturing scale-up, what are your thoughts on payer pricing, and how would winning the XPRIZE HealthSpan grand prize change your strategic plans for age-related frailty? / A: If ELPAS-2 delivers positive data, the company will immediately pursue a partnership with an established pharma. Partners will lead on pricing and commercialization timelines, and no regulatory or commercial blockers are expected for a BLA submission. A priority review voucher is already available for the HLHS indication. For age-related frailty, the company already plans to seek a partnership ahead of any potential XPRIZE win. As the only public company finalist, Longeveron is well-positioned to advance this program regardless of the final competition outcome.

Q: Is the ELPAS-2 SAP fully aligned with the FDA, and was the delay from August to September data release caused by unresolved SAP issues? / A: All prior FDA feedback on endpoint strategy and the SAP has already been incorporated into the submitted plan. The company is still waiting for final FDA comments, but there are no unresolved outstanding issues, and the trial will proceed with the pre-specified plan if no comments are received before database lock. The delay to September was only caused by delays in the 12-month MRI for the last patient visit, not by regulatory or SAP issues.

Q: If the primary RVEF endpoint is not statistically significant, but key secondary clinical endpoints (hospitalization length, transplant-free survival, adverse events) meet significance, can the trial still support a BLA submission and pivotal status? / A: The FDA has already stated it will consider the clinically meaningful events-based endpoints, and has committed to regulatory flexibility for this severe disease with no existing alternative treatments. If the specified secondary endpoints meet statistical significance, the FDA is willing to work with the company to pursue approval, so the trial can still support a BLA filing in this scenario.

Q: Will there be sufficient events-based survival data available at the September readout to support a BLA, and do the endpoints have adequate statistical power? / A: All patients' survival and transplant status will be collected at database lock, with some patients having up to five years of follow-up data already available, which is sufficient to support a BLA submission. A long-term extension trial will continue following patients up to age 10 to collect additional long-term outcome data for regulatory submission. Even with expected missing data, the trial has sufficient patient enrollment to achieve statistical significance on the events-based endpoints if the treatment effect aligns with management's assumptions.